Alnylam partners on heart condition care

Alnylam Pharmaceuticals has announced a new collaboration with Viz.ai and the American Heart Association focused on improving care for patients with ATTR-CM. This partnership aims to leverage technology and medical expertise to enhance patient identification, diagnosis, and management of this serious heart condition. By combining Alnylam's therapeutic focus with Viz.ai's AI-powered care coordination platform and the AHA's extensive reach, the initiative seeks to accelerate access to treatment and improve outcomes for affected individuals.